Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease

Neuron

Volumn 55, Issue 5, 2007, Pages 697-711

  Palop, Jorge J ^a,b   Chin, Jeannie ^a,b   Roberson, Erik D ^a,b   Wang, Jun ^a,b   Thwin, Myo T ^a   Bien Ly, Nga ^a,b   Yoo, Jong ^c   Ho, Kaitlyn O ^a   Yu, Gui Qiu ^a   Kreitzer, Anatol ^a,b   Finkbeiner, Steven ^a,b   Noebels, Jeffrey L ^c   Mucke, Lennart ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

HUMDISEASE; MOLNEURO; SIGNALING

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DENTATE GYRUS; GABAERGIC SYSTEM; HIPPOCAMPUS; MOUSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SIMULATION; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION DISORDERS; DENTATE GYRUS; DISEASE MODELS, ANIMAL; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOCORTEX; NEURAL INHIBITION; NEURAL PATHWAYS; NEURONAL PLASTICITY; NEUROTOXINS; SYNAPTIC TRANSMISSION;

EID: 34548264782     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2007.07.025     Document Type: Article

References (87)

1. Almeida C.G., Tampellini D., Takahashi R.H., Greengard P., Lin M.T., Snyder E.M., and Gouras G.K. β-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 20 (2005) 187-198
2. Amatniek J.C., Hauser W.A., DelCastillo-Castaneda C., Jacobs D.M., Marder K., Bell K., Albert M., Brandt J., and Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47 (2006) 867-872
3. Bakst I., Avendano C., Morrison J.H., and Amaral D.G. An experimental analysis of the origins of somatostatin-like immunoreactivity in the dentate gyrus of the rat. J. Neurosci. 6 (1986) 1452-1462
4. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., and Palmiter R.D. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J. Neurosci. 17 (1997) 8927-8936
5. Bijak M. Inhibitory effect of neuropeptide y on epileptiform activity in the frontal cortex and hippocampus in vitro. Pol. J. Pharmacol. 47 (1995) 461-463
6. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
7. Burgess N., Maguire E.A., and O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron 35 (2002) 625-641
8. Cabrejo L., Guyant-Maréchal L., Laquerriére A., Vercelletto M., De La Fourniére F., Thomas-Antérion C., Verny C., Letournel F., Pasquier F., Vital A., et al. Phenotype associated with APP duplication in five families. Brain 129 (2006) 2966-2976
9. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V.P., Hyman B.T., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2 (1999) 271-276
10. Cheng I., Palop J., Esposito L., Bien-Ly N., Yan F., and Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 10 (2004) 1190-1192
11. Cheng I., Scearce-Levie K., Legleiter J., Palop J., Gerstein H., Bien-Ly N., Puoliväli J., Lesné S., Ashe K., Muchowski P., and Mucke L. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282 (2007) 23818-23828
12. Chin J., Palop J.J., Yu G.-Q., Kojima N., Masliah E., and Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24 (2004) 4692-4697
13. Chin J., Palop J.J., Puoliväli J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., and Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 9694-9703
14. Cobos I., Calcagnotto M.E., Vilaythong A.J., Thwin M.T., Noebels J.L., Baraban S.C., and Rubenstein J.L. Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy. Nat. Neurosci. 8 (2005) 1059-1068
15. Colmers W.F., Lukowiak K., and Pittman Q.J. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J. Physiol. 383 (1987) 285-299
16. Dawson H.N., Ferreira A., Eyster M.V., Ghoshal N., Binder L.I., and Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114 (2001) 1179-1187
17. de Lanerolle N.C., Kim J.H., Robbins R.J., and Spencer D.D. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res. 495 (1989) 387-395
18. Del Vecchio R.A., Gold L.H., Novick S.J., Wong G., and Hyde L.A. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett. 367 (2004) 164-167
19. Diez M., Koistinaho J., Kahn K., Games D., and Hökfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F β-amyloid precursor protein-initial observations. Neuroscience 100 (2000) 259-286
20. Diez M., Danner S., Frey P., Sommer B., Staufenbiel M., Wiederhold K.H., and Hokfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing β-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol. Dis. 14 (2003) 579-594
21. Edwards-Lee T., Ringman J.M., Chung J., Werner J., Morgan A., St George Hyslop P., Thompson P., Dutton R., Mlikotic A., Rogaeva E., and Hardy J. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64 (2005) 377-379
22. Fitzjohn S.M., Morton R.A., Kuenzi F., Rosahl T.W., Shearman M., Lewis H., Smith D., Reynolds D.S., Davies C.H., Collingridge G.L., and Seabrook G.R. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21 (2001) 4691-4698
23. Frankland P.W., and Bontempi B. The organization of recent and remote memories. Nat. Rev. Neurosci. 6 (2005) 119-130
24. Freund T.F., and Buzsáki G. Interneurons of the hippocampus. Hippocampus 6 (1996) 347-470
25. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373 (1995) 523-527
26. 1 receptors. Eur. J. Neurosci. 10 (1998) 757-759
27. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
28. Götz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., and Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9 (2004) 664-683
29. Guzowski J.F., Lyford G.L., Stevenson G.D., Houston F.P., McGaugh J.L., Worley P.F., and Barnes C.A. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J. Neurosci. 20 (2000) 3993-4001
30. Hauser W.A., Morris M.L., Heston L.L., and Anderson V.E. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 36 (1986) 1226-1230
31. He J., Yamada K., and Nabeshima T. A role of Fos expression in the CA3 region of the hippocampus in spatial memory formation in rats. Neuropsychopharmacology 26 (2002) 259-268
32. Hesdorffer D.C., Hauser W.A., Annegers J.F., Kokmen E., and Rocca W.A. Dementia and adult-onset unprovoked seizures. Neurology 46 (1996) 727-730
33. Hsia A., Masliah E., McConlogue L., Yu G., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96 (1999) 3228-3233
34. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., and Malinow R. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
35. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
36. Klapstein G.J., and Colmers W.F. On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus 3 (1993) 103-111
37. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., and Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24 (2004) 8153-8160
38. Kobayashi M., and Buckmaster P.S. Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J. Neurosci. 23 (2003) 2440-2452
39. Kobayashi D.T., and Chen K.S. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav. 4 (2005) 173-196
40. Larner A.J., and Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J. Neurol. 253 (2006) 139-158
41. Lee K.W., Lee S.H., Kim H., Song J.S., Yang S.D., Paik S.G., and Han P.L. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J. Neurosci. Res. 76 (2004) 572-580
42. Link W., Koniezko U., Kauselmann G., Krug M., Schwanke B., Frey U., and Kuhl D. Somatodendritic exprsesion of an immediate early gene is regulated by synaptic activity. Proc. Natl. Acad. Sci. USA 92 (1995) 5734-5738
43. Loscher W., Honack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 8 (1991) 171-189
44. Lozsadi D.A., and Larner A.J. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 22 (2006) 121-124
45. Lyford G.L., Yamagata K., Kaufmann W.E., Barnes C.A., Sanders L.K., Copeland N.G., Gilbert D.J., Jenkins N.A., Lanahan A.A., and Worley P.F. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 14 (1995) 433-445
46. Marcon G., Giaccone G., Cupidi C., Balestrieri M., Beltrami C.A., Finato N., Bergonzi P., Sorbi S., Bugiani O., and Tagliavini F. Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J. Neuropathol. Exp. Neurol. 63 (2004) 199-209
47. 2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 16 (1995) 187-198
48. Marksteiner J., Ortler M., Bellmann R., and Sperk G. Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci. Lett. 112 (1990) 143-148
49. Mathern G.W., Babb T.L., Pretorius J.K., and Leite J.P. Reactive synaptogenesis and neuron densities for neuropeptide Y, somatostatin, and glutamate decarboxylase immunoreactivity in the epileptogenic human fascia dentata. J. Neurosci. 15 (1995) 3990-4004
50. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16 (1993) 409-414
51. Mendez M., and Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 20 (2003) 791-803
52. Mendez M.F., Catanzaro P., Doss R.C., Arquello R., and Frey II W.H. Seizures in Alzheimer's disease: clinicopathologic study. J. Geriatr. Psychiatry Neurol. 7 (1994) 230-233
53. 28K expression. Proc. Natl. Acad. Sci. USA 93 (1996) 8028-8033
54. Morris R.G., Garrud P., Rawlins J.N., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1982) 681-683
55. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
56. Nadler J.V. The recurrent mossy fiber pathway of the epileptic brain. Neurochem. Res. 28 (2003) 1649-1658
57. 28K in temporal lobe epilepsy. J. Neurosci. 20 (2000) 1831-1836
58. O'Keefe J., Nadel L., Keightley S., and Kill D. Fornix lesions selectively abolish place learning in the rat. Exp. Neurol. 48 (1975) 152-166
59. Olney J.W. NMDA receptor hypofunction, excitotoxicity, and Alzheimer's disease. Neurobiol. Aging 16 (1995) 459-461
60. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.-Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100 (2003) 9572-9577
61. Palop J.J., Chin J., Bien-Ly N., Massaro C., Yeung B.Z., Yu G.-Q., and Mucke L. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 25 (2005) 9686-9693
62. Palop J.J., Chin J., and Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 443 (2006) 768-773
63. Peng Z., and Houser C.R. Temporal patterns of fos expression in the dentate gyrus after spontaneous seizures in a mouse model of temporal lobe epilepsy. J. Neurosci. 25 (2005) 7210-7220
64. Plath N., Ohana O., Dammermann B., Errington M.L., Schmitz D., Gross C., Mao X., Engelsberg A., Mahlke C., Welzl H., et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron 52 (2006) 437-444
65. 2+ entry. J. Neurosci. 17 (1997) 8169-8177
66. Rabinowicz A.L., Starkstein S.E., Leiguarda R.C., and Coleman A.E. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer. Dis. Assoc. Disord. 14 (2000) 231-233
67. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
68. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., and Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24 (2004) 3051-3059
69. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.-Q., and Mucke L. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007) 750-754
70. Rothman S.M., and Olney J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 18 (1995) 57-58
71. Salter M.W., and Kalia L.V. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5 (2004) 317-328
72. 2 receptors in an animal model of temporal lobe epilepsy. Mol. Pharmacol. 53 (1998) 6-13
73. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., and Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866-2875
74. Shao L.R., and Dudek F.E. Changes in mIPSCs and sIPSCs after kainate treatment: evidence for loss of inhibitory input to dentate granule cells and possible compensatory responses. J. Neurophysiol. 94 (2005) 952-960
75. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., Verma I.M., and Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8 (2005) 1343-1349
76. Smialowska M., Bijak M., Sopala M., and Tokarski K. Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Neuropeptides 30 (1996) 7-12
77. Snider B.J., Norton J., Coats M.A., Chakraverty S., Hou C.E., Jervis R., Lendon C.L., Goate A.M., McKeel Jr. D.W., and Morris J.C. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch. Neurol. 62 (2005) 1821-1830
78. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., and Greengard P. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8 (2005) 1051-1058
79. Tanzi R., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120 (2005) 545-555
80. Tonder N., Kragh J., Bolwig T., and Zimmer J. Transient decrease in calbindin immunoreactivity of the rat fascia dentata granule cells after repeated electroconvulsive shocks. Hippocampus 4 (1994) 79-83
81. Tonder N., Kragh J., Finsen B.R., Bolwig T.G., and Zimmer J. Kindling induces transient changes in neuronal expression of somatostatin, neuropeptide Y, and calbindin in adult rat hippocampus and fascia dentata. Epilepsia 35 (1994) 1299-1308
82. Tu B., Jiao Y., Herzog H., and Nadler J.V. Neuropeptide Y regulates recurrent mossy fiber synaptic transmission less effectively in mice than in rats: correlation with Y2 receptor plasticity. Neuroscience 143 (2006) 1085-1094
83. Tzingounis A.V., and Nicoll R.A. Arc/Arg3.1: Linking gene expression to synaptic plasticity and memory. Neuron 52 (2006) 403-407
84. Vezzani A., and Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides 38 (2004) 245-252
85. Vezzani A., Sperk G., and Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22 (1999) 25-30
86. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
87. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539